Anonymous
Guest
Anonymous
Guest
Wow, this is the dilemma many scholars have with critics who don't understand how certain markets work. You have this formula where you hear a half way fact, couple your speculations behind it and point guns at a faceless enemy- this case- iroko home office. Yeah they operate like shit, no argument there, but that's how our industry is heading towards. The titans are cutting and closing sales reps left and right, because they have NO MORE NEW IDEAS- get used to it. It's like you're throwing pebbles at brick wall and expecting it break down. Pharma is only going get worse, all these little medical conglomerates that employ multi-specialties are shutting down sampling due to the immense influence by insurance companies who would rather pay for generics. Public doesn't care, it's whatever is the cheapest. Only few docs and patients prefer brands, and get used to that when universal healthcare/lower cost plans take full market presence.
Yeah! You're right of course. This is why every biotech has completely stopped all commercial R&D! Oh wait..... They haven't ! Hmmmm, maybe because there are some products which can still be commercialized and add therapeutic value far in excess of existing generics....and can prove it!